24th week of 2019 has $mnkd 5 yr old Afrezza scripts at New 333 Rxx 397 Label clearly informs : AFREZZA is not a substitute for long-acting insulin. Causes a decline in lung function over time as measured by FEV #Diabetes#T1D#T2D#LiveLife#bloodsugar#insulin $LLY $NOVO $SNY
$UTHR 10Q $mnkd "MannKind has announced that its currently available cash and financing sources are not sufficient to continue to meet its current and anticipated cash requirements, raising substantial doubt about its ability to continue as a going concern $lly $nvs $ibb $xbi
So $mnkd pays Zacks SCR $10's of thousands a year to write " research reports ". Recent paid report is rehash of the June10 poster on P2 N=15 ped study that will eventually have 46 subjects, was started in 2015 and is yrs from completion.
$mnkd baggies excited - founder of Samson hair restoration, who founded Vdex and is mnkd shareholder, feels vdex is disrespected and wants wholesale priced afrezza as "full right" pharmaceutical distributer - because their 3 places in CA and 3 in NM "work". LOL
28 year old $mnkd only drug, 5 year old #Afrezza a gigantic flop as seen by newest scripts. 259 new ones 365 refills. It's own label is clear : provided less HbA1c reduction than insulin aspart, and the difference was statistically significant.
$xbi $ibb $lly $jnj $nvs $nvo $nbi
20th week of 2019 has Nrx 296 Refills 310 Afrezza scripts. Remember $mnkd recently told uthr that they have Substantial doubts about ability to continue as a going concern.